Peptide deformylase: A new target in antibacterial, antimalarial and anticancer drug discovery

Current Medicinal Chemistry

Volumn 22, Issue 2, 2015, Pages 214-236

  Sangshetti, Jaiprakash N ^a   Khan, Firoz A Kalam ^a   Shinde, Devanand B ^b  

^a Y B CHAVAN COLLEGE OF PHARMACY   (India)

^b DR BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY   (India)

Author keywords

Antibacterial; Anticancer; Antimalarial; Clinical developments; Peptide deformylase

Indexed keywords

2,5 DIHYROPYRROLE FORMYL HYRDOXYAMINE DERIVATIVE; 3 METHYLENEPYRROLIDINE FORMYL HYDROXYAMINO DERIVATIVE; ACTINONIN; ALDEHYDE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; AZAAMINO ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; DITHIAZOLE DERIVATIVE; ETHER DERIVATIVE; FUMIMYCIN; HYDROXAMIC ACID DERIVATIVE; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LANOPEPDEN; MACROCYCLIC COMPOUND; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N FORMYL N HYDROXYLAMINE DERIVATIVE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; OXAZOLIDINE DERIVATIVE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PYRROLIDINE DERIVATIVE; THIOL DERIVATIVE; THYROPROPIC ACID; UNCLASSIFIED DRUG; AMIDASE; ENZYME INHIBITOR;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; IC50; INHIBITION CONSTANT; INNATE IMMUNITY; METAL BINDING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULARLY TARGETED THERAPY;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTICARCINOGENIC AGENTS; ANTIMALARIALS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84925455963     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140826115734     Document Type: Article

References (128)

1. World Health Organization. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2001. World Health Report. Geneva, 2002.
2. Carmela, G.; Michele, P.; Thierry, M. Peptide deformylase as target for new generation broad spectrum antimicrobial agents. Mol. Microbiol., 2000, 36(6), 1197-1205.
3. Wenzel, R. P.; Edmond, M. B. Managing antibiotic resistance. N. Engl. J. Med., 2000, 343(3), 1961-1963.
4. Gaynes, R.; Edwards, J. R.; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis., 2005, 41(6), 848-854.
5. D'Agata, E. M. C. Rapidly rising prevalence of nosocomial multidrug-resistant gram-negative bacilli: a 9-year surveillance study. Infect. Control. Hosp. Epidemiol., 2004, 25(10), 842-846.
6. Rice, L. B. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control., 2006, 34(5 Suppl. 1), S11-S19.
7. Aziz, M. A.; Wright, A.; Laszlo, A.; De Muynck, A.; Portaels, F.; Van Deun, A.; Wells, C.; Nunn, P.; Blanc, L.; Raviglione, M. Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): an updated analysis. Lancet, 2006, 368(9553), 2142-2154.
8. Wallis, R. S.; Patil, S.; Cheon, S. H.; Edmonds, K.; Phillips, M.; Perkins, M. D.; Joloba M.; Namale, A.; Johnson, J. L.; Teixeira, L.; Dietze, R.; Siddiqi, S.; Mugerwa, R. D.; Eisenach, K.; Ellner, J. J. Drug tolerance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1999, 43(11), 2600-2606.
9. Kelly, A.; Magdalena, Z. In: Peptide deformylase inhibitors; King and Lawton, Ed.; Elsevier Science B. V: Progress in medicinal chemistry, 2006; Vol. 44, pp. 110-143.
10. Meinnel, T.; Patiny, L.; Ragusa, S.; Blanquet, S. Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry, 1999, 38(14), 4287-4295.
11. Jain, R.; Chen, D.; White, R. J.; Patel, D. V.; Yuan, Z. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem., 2005, 12, 1607-1621.
12. Giglione, C.; Sereo, A.; Pierre, M.; Boisson, B.; Meinnel T. Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J., 2000, 19(21), 5916-5929.
13. th Report). WHO Tech. Rep. Ser., 2000, 892, 1-83.
14. Sachs, J.; Malaney, P. The economic and social burden of malaria. Nature, 2002, 415(6872), 680-685.
15. Kevin, B. J. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother., 2004, 98(41), 4075-4083.
16. Lee, M. D.; Antczak, C.; Li, Y.; Sirotnak, F. M.; Bornmann. W. G.; Scheinberg, D. A. A new human peptide deformylase inhibitable by actinonin. Biochem. Biophy. Res. Commun., 2003, 312(2), 306-315.
17. Serero, A.; Giglione, C.; Sardini, A.; Martinez-Sanz, J.; Meinnel, T. An unusual peptide deformylase features in the human mitochondrial N-terminal methoinine excision pathway. J. Biol. Chem., 2003, 278(52), 52953-52963.
18. David R P Guay. Drug forecast - the peptide deformylase inhibitors as antibacterial agents. Ther. Clin. Risk Manag., 2007, 3(4), 513-525.
19. Jennifer, A. L.; Charles, R. D. Peptide deformylase as an antibacterial target: a critical assessments. Curr. Opin. Pharmacol., 2006, 6(5), 445-452.
20. Zhengyu, Y.; Joaquim, T.; Richard, J. W. Deformylase as a novel antibacterial target. Drug Discov. Today, 2001, 6(18), 954-961.
21. Carmela, G.; Thierry, M. Peptide deformylase as an emerging target for antiparasitic agents. Expert Opin. Ther. Targets, 2001, 5(1), 41-57.
22. Adams, J. M. On the release of the formyl group from nascent protein. J. Mol. Biol., 1968, 33(3), 571-589.
23. Adams, J. M. Capecchi, M. R. N-formylmethionyl-sRNA as the initiator of protein synthesis. Proc. Natl. Acad. Sci. USA., 1966, 55(1), 147-155.
24. Lucchini, G.; Bianchetti, R. Initiation of protein synthesis in isolated mitochondria and chloroplasts. Biochim. Biophys. Acta, 1980, 608(1), 54-61.
25. Meinnel, T.; Mechulam, Y.; Blanquet, S. Methionine as translation start signal: a review of the enzymes of the pathway in Escherichia coli. Biochimie, 1993, 75(12), 1061-1075.
26. Becker, A.; Schlichting, I.; Kabsch, W.; Groche, D.; Schultz, S.; Wagner, A. F. Iron center, substrate recognition and mechanism of peptide deformylase. Nature Struct. Biol., 1998, 5(12), 1053-1058.
27. Mazel, D.; Pochet, S.; Marliere, P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J., 1994, 13(4), 914-923.
28. Takeuchi, N.; Kawakami, M.; Omori, A.; Ueda, T.; Spremulli, L. L.; Watanabe, K. Mammalian mitochondrial methionyl-tRNA transformylase from bovine liver: purification, characterization, and gene structure. J. Biol. Chem., 1998, 273(24), 15085-15090.
29. Takeuchi, N.; Vial, L.; Panvert, M.; Schmitt, E.; Watanabe, K.; Mechulam, Y.; Blanquet, S. Recognition of tRNAs by methionyltRNA transformylase from mammalian mitochondria. J. Biol. Chem., 2001, 276(23), 20064-20068.
30. Bracchi-Richard, V.; Nguyen, K.; Zhou, Y.; Rajagopalan, P. T. R.; Chakrabarti, D.; Pei, D. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys., 2001, 396(2), 162-170.
31. Abhinav, K.; Kiet, T. N.; Sumant, S.; Brad, O.; Stewart, T.; Irwin, H.; Dehua, P.; Wim, G. J. H. Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure, 2002, 10(3), 357-367.
32. Lee, M. D.; She, Y.; Soskis, M. J.; Borella, C. P.; Gardner, J. R.; Hayes, P. A.; Dy, B. M.; Heaney, M. L.; Philips, M. R.; Bornmann, W. G.; Sirotnak, F. M.; Scheinberg, DA. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J. Clin. Invest., 2004, 114(8), 1107-1116.
33. Spencer, A. C.; Spremulli, L. L. Interaction of mitochondrial initiation factor 2 with mitochondrial fMet-tRNA. Nucleic Acids Res., 2004, 32(18), 5464-5470.
34. Giglione, C.; Vallon, O.; Meinnel, T. Control of protein life-span by N-terminal methionine excision. EMBO J., 2003, 22(1), 13-23.
35. Guilloteau, J. P.; Mathieu, M.; Giglione, C.; Blanc, V.; Dupuy, A.; Chevrier, M.; Gil, P.; Famechon, A.; Meinnel, T. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol., 2002, 320(5), 951-962.
36. Meinnel, T. Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents. Parasitol. Today, 2000, 16(4), 165-168.
37. Mazel, D.; Pochet, S.; Marliere, P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J., 1994, 13(4), 914-923.
38. Groche, D.; Becker, A.; Schlichting, I.; Kabsch, W.; Schultz, S.; Wagner, A. F. Isolation and crystallization of functionally competent Escherichia coli peptide deformylase forms containing either iron or nickel in the active site. Biochem. Biophys. Res. Comm., 1998, 246(2), 342-346.
39. Rajagopalan, P. T. R.; Yu, X. C.; Pei, D. Peptide deformylase, a new type of maononuclear iron protein. J. Am. Chem. Soc., 1997, 119(50), 12418-12419.
40. Rajagopalan, P. T.; Pei, D. Oxygen mediated inactivation of peptide deformylase. J. Biol. Chem., 1998, 273(35), 22305-22310.
41. Meinnel, T.; Lazennec, C.; Dardel, F.; Schmitter, J. M.; Blanquet, S. The C-terminal domain of peptide deformylase is disordered and dispensable for activity. FEBS Lett., 1996, 385(1-2), 91-95.
42. Meinnel, T.; Lazennec, C.; Dardel, F.; Viloing, S.; Blanquet, S. Structure-function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and metal ion. J. Mol. Biol., 1997, 267(3), 749-761.
43. Chang, M. K.; Gong, W.; Rajagopalan, P. T.; Hao, B.; Tsai, C. M.; Pei, D. Crystal structure of the Escherichia coli peptide deformylase. Biochemistry, 1997, 36(45), 13904-13909.
44. Becker, A.; Schlichting, I.; Kabsch, W.; Schultz, S.; Wagner, A. F. Structure of peptide deformylase and identification of the substrate binding site. J. Biol. Chem., 1998, 273(19), 11413-11416.
45. Dardel, F.; Ragusa, S.; Lazennec, C.; Blanquet, S.; Meinnel, T. Solution structure of nickel-peptide deformylase. J. Mol. Biol., 1998, 280(3), 501-513.
46. Smith, K. J.; Petti, C. M.; Aubart, K.; Symth, M.; McManus, E.; Jones, J.; Fosberry, A.; Lewis, C.; Lonetto, M.; Christensen, S. B. Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Sci., 2003, 12(2), 349-360.
47. Kreusch, A.; Spraggon, G.; Lee, C. C.; Klock, H.; McMullan, D.; Ng, K.; Shin, T.; Vincent, J.; Warner, I.; Ericson, C.; Lesley, S. A. Structure analysis of peptide deformylases from Streptococcus pneumoniae, Staphylococcus aureus, Thermotoga maritima and Pseudomonas aeruginosa: snapshots of the oxygen sensitivity of peptide deformylase. J. Mol. Biol., 2003, 330(2), 309-321.
48. Hu, Y.; Wei, Y.; Zhou, Y.; Rajagopalan, P. T.; Pei, D. Determination of substrate specificity for peptide deformylase through the screening of a combinatorial peptide library. Biochemistry, 1999, 38(2), 643-650.
49. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem., 2000, 43(3), 305-341.
50. Chen, D. Z.; Patel, D. V.; Hackbarth, C. J.; Wang, W.; Dreyer, G.; Young, D. C.; Margolis, P. S.; Wu, C; Ni, Z. J.; Trias, J.; White, R. J.; Yuan, Z. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry, 2000, 39(6), 1256-1262.
51. Fu, H.; Dahlgren, C; Bylund, J. Subinhibitory concentrations of the deformylase inhibitor actinonin increase bacterial release of neutrophil-activation peptides: a new approach to antimicrobial chemotherapy. Antimicrob. Agents Chemother., 2003, 47(8), 2545-2550.
52. Gross, M.; Clements, J.; Beckett, R. P.; Thomas, W.; Taylor, S.; Lofland, D.; Ramanathan-Girish, S.; Garcia, M.; Difuntorum, S.; Hoch, U.; Chen, H.; Johnson, K. W. Oral antipneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J. Antimicrob. Chemother., 2004, 53(3), 487-493.
53. Yaoming, W.; Tian, Y.; Kristi, M. H.; Chaity, C; Dehua, P. Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J. Comb. Chem., 2000, 2(6), 650-657.
54. Kristi, M. H.; Tian, Y.; Yaoming, W.; Dehua, P. Synthesis and Antibacterial Activity of Peptide Deformylase Inhibitors. Biochemistry, 2000, 39(15), 4543-4551.
55. Yun-Jin, H.; Rajagopalan, P. T. R.; Dehua, P. H-phosphonate derivatives as novel peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 1998, 8(18), 2479-2482.
56. Daniel, J. D.; Barbara, G. G.; John, F. O.; Stephan, K. G. Peptide aldehyde inhibitors of bacterial peptide deformylases. Arch. Biochem. Biophys., 1999, 367(2), 297-302.
57. Smith, H. K.; Beckett, R. P.; Clements, J. M.; Doel, S.; East, S. P.; Launchbury, S. B.; Pratt, L. M.; Spavold, Z. M.; Thomas, W.; Todd, R. S.; Whittaker, M. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the metal binding group. Bioorg. Med. Chem. Lett., 2002, 12(24), 3595-3599.
58. Clements, J. M.; Beckett, R. P.; Brown, A.; Catllin, G.; Lobell, M.; Palan, S.; Thomas, W.; Whittaker, M.; Wood, S.; Salama, S.; Baker, P. J.; Rodgers, H. F.; Barynin, V.; Rice, D. W.; Hunter, M. G. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase Inhibitor. Antimicrob. Agents Chemother., 2001, 45 (2) 563-570.
59. Corinne, J. H.; Dawn, Z. C.; Jason, G. L.; Kirk, C; James, B. M.; Jeffrey, A. C.; Peter, S. M.; Wen, W.; Jim, K.; Charlotte, W.; Lopez, S.; George, W. I.; Helen, G.; Elina, D.; Kulathia, R.; Shi-Hao, P.; Wilma, L. P.; Jeff, J.; Joaquim, T.; Dinesh, V. P.; Beat, W.; Richard, J. W.; Zhengyu, Y. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother., 2002, 46(9), 2752-2764.
60. Jain, R.; Sundram, A.; Lopez, S.; Neckermann, G.; Wu, C; Hackbarth, C; Chen, D.; Wang, W.; Ryder, N. S.; Weidmann, B.; Patel, D.; Trias, J.; White, R.; Yuan, Z. α-Substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents. Bioorg. Med. Chem. Lett., 2003, 13(23), 4223-4228.
61. Arkadius, P.; Jeyaraj, D.; Zheng, Y.; Thomas, H. K.; Jenefer, A.; Sarah, L.; Gladys, L.; Mei, D.; Gang, W.; Wai, L. C.; Mark, S.; Ida, M.; David, B.; Xinyi, N.; Kakoli, M.; Mahesh, N.; Jeanette, W. P. T.; Pamela, T.; Amelia, Y.; Thomas, D.; Wuyi, M.; Mei, X.; James K.; Shi-Hao P.; Kirk C; Xiaoling X.; Carolyn S.; Michael C. Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. Bioorg. Med. Chem. Lett., 2008, 18(24), 6568-6572.
62. Zhenyu, W.; Weicheng, Z. Syntheis and in vitro antibacterial activity of (2S)-N-(substitutedphenyl)-1-[2R)-2-[(formylhyroxyamino) methyl]-1-oxohexyl]-2-pyrrolidine carboxamides as potential peptide deformylase inhibitors. Chem. Biol. Drug Des., 2009, 73(1), 142-146.
63. Jeffrey, M. A.; Jesus, R. M.; Charles, W. B.; Celine, D.; Seth, W. G.; Mark, A. B.; Tony, P.; William, H. M.; Theresa, P.; Timothy, F. G.; Swarupa, K.; Thomas, L.; Glenn, S. V. A.; Rimma, Z.; Paris, W.; Nino, C. Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity. Bioorg. Med. Chem. Lett., 2012, 22(12), 4028-4032.
64. Wei, S.; Yuejiao, D.; Yu, Q.; Ming, L.; Liping, Y.; Wenhao, H. Design, synthesis and antibacterial activity of 2, 5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(12), 3592-3595.
65. Wei, S.; Haikun, M.; Yuejiao, D.; Kelly, A.; Yuhong, F.; Rimma, Z.; Liping, Y.; Wenhao, H. Design, synthesis and antibacterial activity of 3-methylenepyrrolidine formyl hydroxyamino derivatives as novel peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(3), 1060-1063.
66. Ii, K.; Ichikawa, S.; Al-Dabhagh, B.; Bouhss, A.; Matsuda, A. Function-oriented synthesis of simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria. J. Med. Chem., 2010, 53(9), 3793-3813.
67. Keller, M.; Boissard, C; Patiny, L.; Chung, N. N.; Lemieux, C; Mutter, M.; Schiller, P. W. Pseudoproline-Ccontaining analogues of morphiceptin and endomorphin-2: evidence for a Cis Tyr-Pro amide bond in the bioactive conformation. J. Med Chem., 2001, 44(23), 3896-3903.
68. Tuchscherer, G.; Grell, D.; Tatsu, Y.; Durieux, P.; Fernandez-Carneado, J.; Hengst, B.; Kardinal, C; Feller, S. Targeting molecular recognition: exploring the dual role of functional pseudoprolines in the design of SH3 ligands. Angew. Chem., Int. Ed., 2001, 40(15), 2844.
69. Linliang, Y.; Weicheng, Z.; Zhenyu, W. Synthesis and in vitro antibacterial activity of oxazolidine LBM-415 analogsas peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (5) 1541-1544.
70. Zega, A. Azapeptides as pharmacological agents. Curr. Med. Chem., 2005, 12(5), 589-597.
71. Stephen P. E.; Andrew A.; Ian T.; Steven T.; Wayne T. Peptidomimetic inhibitors of bacterial peptide deformylase. Bioorg. Med. Chem. Lett., 2011, 21(13), 4032-4035.
72. Maithri, M. K. J.; Ann, K.; Ramy, S.; Michael, D.; Mathew, T.; Martin, A. S.; Tod, P. H. Novel nonpeptidic inhibitors of peptide deformylase. Arch. Biochem. Biophys., 2000, 381(2), 313-316.
73. Bhat, A.; Christensen, S. B.; Frazee, J. S.; Head, M. S.; Leber, J. D.; Li, M. Peptide deformylase inhibitors. PCT Int. Appl. WO 02, 081, 426. Chem. Abstr., 2002, 137, 310696.
74. Bhat, A.; Christensen, S. B.; Frazee, J. S.; Head, M. S.; Leber, J. D.; Li, M. Peptide deformylase inhibitors. PCT Int. Appl. WO 03, 002, 522, Chem. Abstr., 2003, 138, 89584.
75. 6-benzo[1, 2, 6]thiadiazin-3-yl)-N-hydroxyacetamides as potent and selective peptide deformylase inhibitors. J. Med. Chem. 2001, 44(12), 1847-1852.
76. Valentina, M.; Xiaohui, H.; Juliet, N.; Kunyong, Y.; Andreas, K.; Perry, G.; Badry, B.; Ian, W.; Tanya, S.; Tanya, B.; Neil, S. R.; Ron, G.; John, D.; Yun, H. Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (6) 1477-1481.
77. Apfel, C; Banner, D. W.; Bur, D.; Dietz, M.; Hirata, T.; Hubschwelen, C; Locher, H.; Page, M. G. P.; Pirson, W.; Rosse, G.; Specklin, J. Hydroxamic Acid Derivatives as Potent Peptide Deformylase Inhibitors and Antibacterial Agents. J. Med. Chem., 2000, 43(12), 2324-2331.
78. Barbara, G. G.; Jeffrey, H. T.; John, W. K.; Stephan, K. G. Inhibition of bacterial peptide deformylase by biaryl acid analogs. Arch. Biochem. Biophys., 2000, 375(2), 355-358.
79. Aubart, K. M.; Christensen, S. B.; Briand, J.; Cummings, M. D. Peptide deformylase inhibitors. U. S. Patent 6, 806, 369, October 19, 2004.
80. Christensen, S. B.; Cummings, M. D.; Karpinski, J. M. Peptide deformylase inhibitors. U. S. Patent 6, 852, 882, February 8, 2005.
81. Wataru, T.; Yoshihisa, S.; Yusuke, S.; Emi, N.; Shuhei, F.; Kanako, S.; Jun, I. Synthesis and PDF inhibitory avtivities of novel benzothiazolylidenehydroxamic acid derivatives. Bioorg. Med. Chem. Lett., 2003, 13(19), 3273-3276.
82. Patrizia, C; Lars, N.; Seema, M.; Anders, H. Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. Bioorg. Med. Chem. Lett., 2004, 14(24), 5997-6000.
83. Xubo H.; Kiet T. N.; Christophe L. M. J. V.; Wim G. J. H.; Dehua P. Structure-based design of a macrocyclic inhibitor for peptide deformylase. J. Med. Chem. 2003, 46(18), 3771-3774.
84. Gang, S.; Jinge, Z.; Anthony, M. S.; Dehua, P. Design and synthesis of macrocyclic peptidyl hydroxamates as peptide deformylase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(10), 3060-3063.
85. Ling, Y.; Wei-Ren, X.; Zhi-Guo, W.; Da-Tong, Z.; Jiong, J.; Yan-Qing, G.; Yan, L.; Jian-Wu, W. Synthesis and antimicrobial activities of novel peptide deformylase inhibitors. ARKIVOC, 2010, 9(9), 196-205.
86. Boularot, A.; Giglione, C.; Artaud, I.; Meinnel, T. Structureactivity relationship and therapeutic potential of peptide deformylase inhibitors. Curr. Opin. Invest. Drug., 2004, 5(8), 809-822.
87. Fieulaine, S.; Juillan-Binard, C.; Serero, A.; Dardel, F.; Giglione, C.; Meinnel, T.; Ferrer, J. L. The crystal structure of mitochondrial (type IA) peptide deformylase provides clear guidelines for the design of inhibitors specific for the bacterial forms. J. Biol. Chem., 2005, 280(51), 42315-42324.
88. Serero, A.; Giglione, C.; Meinnel, T. Distinctive features of the two classes of eukaryotic peptide deformylases. J. Mol. Biol., 2001, 314(4), 695-708.
89. Adrein, B.; Carmela, G.; Sylvain, P.; Yann, D.; Rodolphe, A. S.; Valery, L.; Thierry, C.; Frederic, D.; Isabelle, A.; Thierry, M. Discovery and refinement of a new structural class of potent peptide deformylase inhibitors. J. Med. Chem., 2007, 50(1), 10-20.
90. Sylvain, P.; Yann, D.; Valery, L.; Carmela, G.; Carole, L.; Coralie, S.; Alexis, D.; Frederic, D.; Thierry, M.; Isabelle, A. Structureactivity relationship analysis of the peptide deformylase inhibitor 5-bromo-1H-indole-3-acetohydroxamic acid. ChemMedChem, 2009, 4(2), 261-275.
91. Alexander, K. B.; Qingfeng, Y.; Steven, Y. Q.; Manas, K. H.; Srivastava, D. K. Solvent-assisted slow conversion of a dithiazole derivative produces a competitive inhibitor of peptide deformylase. Biochim. Biophys. Acta, 2010, 1804(4), 704-713.
92. Jung-Sung, Y.; Chang-Ji, Z.; Sangku, L.; Jin-Hwan, K.; Won-Gon, K. Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus sabtilis. Bioorg. Med. Chem. Lett., 2006, 16(18), 4889-4892.
93. Kwon, Y. J.; Sohn, M. J.; Zheng, C. J.; Kim, W. G. Fumimycin: a peptide deformylase inhibitor with an unusual skeletal produced by Aspergillus fumisynnematus. Org. Lett., 2007, 9(13), 2449-2451.
94. Zhi-Wang, Z.; Wei-Chao, L.; Yu, H.; Bin, W.; Gang, R.; Li-Hua, F. Synthesis of the intermediate for fumimycin: a natural peptide deformylase inhibitor. Res. Chem. Intermediat., 2013, 39(7), 3049-3054.
95. Kwon, Y. J.; Sohn, M. J.; Zheng, C. J.; Kim, W. G. Isolation and identification of FR198248, a hydroxylated 1, 3-dihydroisobenzofuran Asperrgillus flavipes as an inhibitor of peptide deformylase. Biosci. Biotechnol. Biochem., 2010, 74(2), 90565-90568.
96. Kunqiang, C.; Weiqiang, L.; Lili, Z.; Xu, S.; Jin, H. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochem. Biophys. Res., 2013, 435(2), 289-294.
97. Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Beck, E.; Jomaa, H. Seeking new targets for antiparasitic agents. Trends Parasitol., 2001, 17(1), 7-8.
98. Wiesner, J.; Seeber, F. The plastid derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets, 2005, 9(1), 23-44.
99. Mark, A. R.; Kiet, T. N.; Abhinav, K.; Irwin, H.; Stewart, T.; Dehua, P.; Wim, G. J. H. An improved crystal form of Plasmodium falciparum peptide deformylase. Protein Sci., 2004, 13(4), 1155-1163.
100. Amina, M.; Abdelouahab, C.; Abderrahmane, B.; Khadidja, S. H.; Hanane, B.; El-Hassen, M.; Soumia, T. Study on the antimalarial activity of actinonin derivatives my molecular modeling. Trends Bioinform., 2013, 6(1), 17-24.
101. Sindy, E.; Yehuda, G.; Guangli, Y.; Ouathek, O.; Yueming, L.; David, A. S. Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J. Mol. Biol., 2009, 387(5), 1211-1228.
102. Nguyen, K. T.; Hu, X. C.; Colton, R.; Chakrabarti, M.; Zhu, X.; Pei, D. Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry, 2003, 42(33), 9952-9958.
103. Xu, Y.; Lai, L. T.; Gabrilove, J. L.; Schienberg, D. A. Antitumor activity of actinonin in vitro and in vivo. Clin. Cancer Res., 1998, 4(1), 23-44.
104. Mona, D. L.; Chritophe, A.; Yueming, L.; Francis, M. S.; William, G. B.; David, A. S. A new human peptide deformylase inhibitable by actinonin. Biochem. Biophys. Res., 2003, 312(2), 309-315.
105. Mona, D. L.; Yuhong, S.; Michael, J. S.; Christopher, P. B.; Jeffrey, R. G.; Paula, A. H.; Benzon, M. D.; Mark, L. H.; Mark, R. P.; Willium, G. B.; Francis, M. S.; David, A. S. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J. Clin. Invest., 2004, 114(8), 1107-1116.
106. Sang, J. L.; Ok, S. J.; Bong-Jin, L.; Kwang-Hwi, C.; Byung, I. L. Identification of potent inhibitors against human peptide deformylase as anticancer agents. Bull. Korean Chem. Soc., 2013, 34(1), 1-3.
107. Christophe, A.; David, S.; Sindy, E.; Bhiramdeo, B.; Earl, K.; Venkatraman, E. S.; Nian, W.; Guangli, Y.; Ouathek, O.; Yue-Ming, L.; David, A. S.; Hakim, D. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J. Biomol. Screen, 2007, 12(4), 521-535.
108. Christophe, A.; David, S.; Bhiramdeo, B.; Mark, G. F.; Yue-Ming, L.; Elisa, S.; David, A. S.; Hakim, D. Identification of benzofuran-4, 5-diones as novel and selective non-hydroxamic acid, nonpeptidomimetic based inhibitors of human peptide deformylase. Bioorg. Med. Chem. Lett., 2011, 21(15), 4528-4532.
109. Hao, B.; Gong, W.; Rajagopalan, P. T.; Zhou, Y.; Pei, D.; Chan, M. K. Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry, 1999, 38 (15) 4712-4719.
110. Molteni, V.; He, X.; Nabakka, J.; Yang, K.; Kreusch, A.; Gordon, P.; Bursulaya, B.; Warner, I.; Shin, T.; Biorac, T.; Ryder, N. S.; Goldberg, R.; Doughty, J.; He, Y. Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(6), 1477-1481.
111. Yoon, H. J.; Kim, H. L.; Lee, S. K.; Kim, H. W.; Kim, H. W.; Lee, J. Y.; Mikami, B.; Suh, S. W. Crystal structure of peptide deformylase from Staphylococcus aureus in complex with actinonin, a naturally occurring antibacterial agent. Proteins, 2004, 57(3), 639-642.
112. Zhou, Z.; Song, X.; Gong, W. Novel conformational states of peptide deformylase from pathogenic bacterium Leptospira interrogans: implications for population shift. J. Biol. Chem., 2005, 280(51), 42391-42396.
113. Cai, J.; Han, C.; Hu, T.; Zhang, J.; Wu, D.; Wang, F.; Liu, Y.; Ding, J.; Chen, K.; Yue, J.; Shen, X.; Jiang, H. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci. 2006, 15(9), 2071-2081.
114. Lee, S. J.; Lee, S. J.; Lee, S. K.; Yoon, H. J.; Lee, H. H.; Kim, K. K.; Lee, B. J.; Lee, B. I.; Suh, S. W. Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors. Acta Cryst., 2012, D68 (7) 784-793.
115. Jian, G.; Yuanhua, C.; Wei, C.; Quan, C.; Fushi, Z.; Yuguo, D.; Mingjuan, J. 3D-QSAR and molecular docking studies of hydroxamic acids as peptide deformylase inhibitors. Med. Chem. Res., 2012, 21(8), 1597-1610.
116. Ji, Y. L.; Munikumar, R. D.; Yong, S. C.; Hyunah, C.; Hun, Y. K.; Jae-Hoon, K.; Kyoung, T. N.; Ae, N. P. Comparative QSAR studies on peptide deformylase inhibitors. J. Mol. Model., 2007, 13(12), 543-558.
117. Manish, K. G.; Pradeep, M.; Philip, P.; Anil, K. S. 2D-QSAR in hydroxamic acid derivatives as peptide deformylase inhibitors and antibacterial agents. Bioorg. Med. Chem., 2002, 10(12), 3713-3716.
118. Itishree, S. V.; Kaumudi, S. P.; Krishnacharya, A. Designing of novel peptide deformylase inhibitors by a comparative molecular field analysis. IJAPR., 2011, 2(7), 405-411.
119. http://www.clinicaltrials.gov dated 20/12/2013.
120. Karen, O.; Meredith, H.; Sarah, H.; Daryl, H.; Samuel, B.; Donghui, Q.; Kelly, A.; Magdalena, Z.; Deborah, B. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob. Agents Chemother., 2013, 57(5), 2333-2342.
121. Azoulay-Dupuis, E.; Mohler, J.; Bedos, J. P. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob. Agents Chemother., 2004, 48(1), 80-85.
122. Ramanathan-Girish, S.; McColm, J.; Clements, J. M.; Taupin, P.; Barowcliffe, S.; Hevizi, J.; Safrin, S.; Moore, C.; Patou, G.; Moser, H.; Gadd, A.; Hoch, U.; Jiang, V.; Lofland, D.; Johnson, K. W. Antimicrob. Agents Chemother., 2004, 48(12), 4835-4842.
123. Rolan, P.; Sun, H.; MacLeod, C.; Bracken, K.; Evans, T. G. Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor. Clin. Pharmacol. Ther., 2011, 90(2), 256-262.
124. Teo, J. W. P.; Thayalan, P.; Beer, D.; Yap, A. S. L.; Nanjundappa, M.; Ngew, X.; Duraiswamy, J.; Liung, S.; Dartois, V.; Schreiber, M.; Hasan, S.; Cynamon, M.; Ryder, N. S.; Yang, X.; Weidmann, B.; Bracken, K.; Dick, T.; Mukherjee, K. Peptide deformylase inhibitors as potent antimicrobial agents. Antimicrob. Agents Chemother., 2006, 50(11), 3665-3673.
125. Christian, M. A.; Hans, L.; Stefan, E.; Bela, T.; Christain, H.; Wolfgang, P.; Malcolm, G. P. P.; Wolfgang, K. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother., 2001, 45(4), 1058-1064.
126. Dean, C. R.; Narayan, S.; Daigle, D. M.; Dzink-Fox, J. L.; Puyang X.; Bracken, K. R.; Dean, K. E.; Weidmann, B.; Yuan Z.; Jain R.; Ryder, N. S. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemiphilus influenza to the novel peptide deformylase inhibitors LB415. Antimicrob. Agents Chemother., 2005, 49(8), 3129-3135.
127. Nilsson, A. I.; Zorzet, A.; Kanth, A.; Dahlstrom, S.; Berg, O. G.; Andersson, D. I. Reducing the fitness costs of antibiotic resistance by the amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA., 2006, 103(18), 6976-6981.
128. Carmela, G.; Thierry, M. Resistance to anti-peptide deformylase drugs. Expert Opin. Ther. Targets, 2001, 5(3), 415-418.